C2N Diagnostics

About:

C2N Diagnostics, LLC is a privately held protein diagnostic and therapeutic discovery company.

Top Investors: Alzheimer's Drug Discovery Foundation, GHR Foundation, Eisai US

Description:

C2N Diagnostics, LLC is a privately held protein diagnostic and therapeutic discovery company targeting progressive neurodegeneration. They formed in late 2007 by scientific co-founders Drs. David Holtzman and Randall Bateman of Washington University School of Medicine in St. Louis, and LifeTech Research, a Maryland-based technology research and commercialization firm (www.lifetechresearch.com). They reside at the Center for Emerging Technologies in St. Louis.

Total Funding Amount:

$74.2M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Saint Louis, Missouri, United States

Founded Date:

2007-01-01

Contact Email:

info(AT)C2NDiagnostics.com

Founders:

David Holtzman, Joel B. Braunstein, Randall Bateman

Number of Employees:

11-50

Last Funding Date:

2024-09-25

IPO Status:

Private

Industries: